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Abstract: New clinical indications for rituximab seem to appear every day. This review will 
trace the use of this monoclonal antibody from lymphoid malignancy, to classic autoimmune 
disease, and specifically severe autoimmune skin diseases. The history leading to different dosing 
schema with associated pharmacokinetic data will be discussed. A case of livedoid vasculopathy 
(atrophie blanche) responding to rituximab will illustrate how the response to therapy can help 
to elucidate previously obscure pathophysiology.
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Introductory case
A 49-year-old man diagnosed with livedoid vasculopathy (LV) (atrophie blanche) is 
referred by dermatology to the hematology clinic for consideration of rituximab therapy. 
The referring physician had previously treated the patient with systemic corticosteroids 
as well as multiple steroid sparing immunosuppressive, anticoagulant, and fibrinolytic 
regimens. Despite compliance, the patient developed corticosteroid-induced diabetes 
mellitus with lower extremity neuropathy and was unable to work due to painful lower 
extremity ulcerative lesions requiring opioid analgesia.
The diagnosis of LV had been made by an outside dermatologist after a biopsy 
of the skin and an evaluation at another tertiary referral center. Upon presentation to 
our dermatology clinic, he had painful ulcers and white stellate scars involving both 
lower legs, ankles and dorsal feet consistent with a diagnosis of LV . The patient’s 
ulcers typically healed with tapering courses of prednisone beginning at 1 mg/kg 
daily; however, he found that he could rarely go without prednisone for more than 
two weeks. He was taking colchicine 0.6 mg twice daily as a steroid sparing agent 
and had previously failed therapy with pentoxyphylline and aspirin.
Prior to and after presentation to our clinic, the patient underwent an   extensive 
  laboratory evaluation to assess for autoimmune or procoagulant disorders.   Studies 
that were either negative or within normal limits included: antineutrophil   cytoplasmic 
  antibodies, cryoglobulins, rheumatoid factor, lupus anticoagulant screen,   anticardiolipin 
  antibodies, prothrombin time, activated partial thromboplastin time, platelet 
count,   hepatitis B and C serologies, homocysteine, erythrocyte sedimentation rate, 
  complement levels, functional protein C and S, and factor V Leiden mutation analysis. 
Antinuclear antibodies were positive at titers of 1:160 and 1:80 on two separate occa-Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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sions. An incisional biopsy performed at an outside facility 
was evaluated by a dermatopathologist and was felt to be 
  consistent with a diagnosis of LV .
Over the course of three years, the patient was treated with 
multiple agents. Dapsone 50 mg daily provided no benefit; 
however, clopidogrel bisulfate 75 mg daily combined with 
colchicine 0.6 mg twice daily initially produced significant 
improvement with a dramatic reduction in the patient’s need 
for prednisone. Unfortunately, the patient’s disease flared-up 
again after several months. Azathioprine 100 mg daily was 
added twice although discontinued secondary to elevated 
transaminases first and transient leukopenia second. Stanazol 
also failed to produce any improvement. The patient required 
prednisone as high as 80 mg daily, and his course was 
complicated by the development of mononeuritis multiplex 
involving both lower extremities as well as corticosteroid-
induced diabetes mellitus.
A single case report describing the successful treatment 
of this condition with rituximab accompanied the consulta-
tion request.1 The patient was treated with two cycles of 
rituximab 1000 mg delivered two weeks apart. Figure 1 
demonstrates response to therapy. A recurrence of his disease 
seven months later responded quickly to further treatment 
with rituximab.
Livedoid vasculopathy 
(atrophie blanche)
LV is characterized by the development of painful purpuric 
and petechial lesions on the lower extremities. The lesions 
evolve to “punched-out” ulcers that heal with white, stellate 
scars. Biopsies of involved skin typically show little inflam-
mation and hyalinized vessels.2 Neuropathy in association 
with LV has been described.3 While pathogenesis is obscure, 
the clinical findings of LV have been associated with both 
procoagulant and autoimmune diseases.4,2 Others have 
reported clinical LV associated with vasculitis.5 The clinical 
findings have multiple competing and overlapping putative 
mechanisms, including hypercoagulability, autoimmunity, 
and idiopathic mechanisms.
Zeni and colleagues reported a single case of LV 
  successfully treated with rituximab 1000 mg two weeks apart.1 
Their patient, like ours, required systemic corticosteroids and 
had failed multiple steroid sparing agents and anticoagulants. 
The response of these two patients suggests that inflammation 
plays an important role in the pathogenesis of LV , at least in 
some patients. The purpose of this review is to briefly trace the 
history of rituximab in clinical use, explain the rationale for 
this agent in the treatment of   auto-inflammatory skin disease, 
and to discuss dosing in novel disease indications.
The story of rituximab
Rituximab is a chimeric monoclonal immunoglobulin (Ig) 
IgG antibody targeted against the CD20 epitope on mature 
normal and malignant B-lymphocytes. The IgG1 and κ con-
stant regions are human, while the variable regions are murine. 
Rituximab was US Food and Drag Administration (FDA) 
approved for treatment of follicular non-Hodgkin   lymphoma in 
1997 on the basis of encouraging phase II and III data reporting 
a durable response rate of 46% in heavily pretreated patients 
with less toxicity than cytotoxic chemotherapy.6
Rituximab was the first monoclonal antibody to enter 
routine use in clinical oncology and has since been demon-
strated to improve survival in both indolent and aggressive 
histology non-Hodgkin lymphoma.7,8
Figure 1 Livedoid vasculopathy successfully treated with rituximab. A 49-year-old 
man with reclaitrant ulcers of the lower extremities before (A) and 3-months after 
(B) treatment with 1000 mg of rituximab infused twice 14 days apart.Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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Mechanism of action
In many ways, determining the mechanism of action of 
  rituximab in lymphoma was straightforward. Rituximab 
binding was demonstrated on interim lymph node biopsies 
in responding patients. Antibody-dependent cell-mediated 
cytotoxicity and direct apoptosis of malignant B-cells was 
implicated. The concern with the initial clinical use of ritux-
imab was that a complete knockout of normal peripheral 
B-lymphocytes could occur. Indeed it did occur in the first 
trial. Complete absence of peripheral blood B-lymphocytes 
occurred within one week of initial therapy and persisted 
until six months when gradual recovery ensued. Surprisingly, 
there was no significant increase in infections compared to 
the baseline experienced by heavily pretreated lymphoma 
patients.
Rituximab did not lead to decreases in immunoglobulin 
or complement levels either. Although one patient   developed 
detectable human anti-chimeric antibodies these were not 
quantifiable and did not have any clinical significance. 
  Rituximab levels in serum increased with subsequent treat-
ment. A subset of nine patients had detailed pharmacoki-
netic sampling with a mean maximum concentration of 
500 ± 135.2 µg/mL (range, 201.4 to 663 µg/mL) and serum 
antibody half-life (t½) values from 12.7 to 370.8 hours (mean 
t½ of 225.9 ± 102.7 hours).6 Responding patients had higher 
rituximab levels prior to second infusion.
The adverse events associated with the first reports of 
rituximab were infusion related and tended to be manage-
able with outpatient care. In addition, these side effects less-
ened with subsequent administrations during a four-week 
course of 375 mg/m2 per treatment. Rituximab is routinely 
prescribed for all non-Hodgkin lymphoma bearing the CD 
20 antigen. It has been one of two drugs in hematologic 
malignancy (imatinib mesylate being the other) that has 
dramatically changed the treatment landscape in the last 
fifteen years.
Rituximab in autoimmune disease
Rheumatoid arthritis (RA) is a classic multisystem autoimmune 
disease that affects 1% of the world’s population. Women are 
three to five times more often affected than men, most commonly 
in the middle–elderly age range (40–70). Rheumatoid factor 
(present in 80% of individuals with RA) is an IgM autoantibody 
to the Fc portion of autologous IgG. Rheumatoid factor com-
plexes with its target and can be found in serum, synovial fluid 
and synovial membranes. It is diagnostically important, although 
it is not believed to be causative for the disease.9
In fact, RA has classically been conceptualized as a T-cell 
mediated disease. Past and modern therapeutic efforts in 
RA have focused on cell mediated immunity or cytokines 
(particularly tumor necrosis factor) produced by T-cells. That 
understanding of RA pathophysiology was altered by reports of 
successful treatment with rituximab. Edwards and colleagues 
described the treatment of 161 patients with severe RA with 
methotrexate alone versus one of three regimens containing 
rituximab 1000 mg fixed dose on days 1 and 15.10 Significant 
clinical improvement in disease symptoms was realized at 24 
and 48 weeks in rituximab treated patients. Adverse events 
mirrored past clinical experience with non-Hodgkin lymphoma 
and tended to involve mild-moderate infusion toxicity.
A subsequent pharmacokinetic study of this trial 
described a basic two-compartment model with linear 
elimination pharmacokinetics.11 Typical clearance (CL) 
was 276 mL/day and typical central volume of distribu-
tion (Vc) of rituximab was 2980 mL or 45 mg/kg, which 
is equal to human plasma volume. These investigators also 
demonstrated an increasing t½ of rituximab with subsequent 
infusions. The distribution half-life was 2.4 days while the 
elimination half-life was 19.7 days. The first phase repre-
sented elimination of rituximab and distribution from the 
intravascular to extravascular space. During the second 
(terminal) phase antibody concentrations slowly declined 
predominately due to elimination. Covariate analysis to 
uncover causes of interindividual variability revealed body 
surface area (BSA) and gender as most significant. However, 
BSA was only responsible for 19.7% of interindividual vari-
ability suggesting that although BSA predicted CL, the effect 
may not be highly contributory. These authors interpreted 
the data to support fixed dosing of rituximab for rheumatoid 
arthritis. Intravenous (IV) administration of two doses of 
1000 mg given two weeks apart is the FDA-approved dose 
for RA and is widely used in clinical practice.
Rituximab in autoimmune skin 
disorders
Pemphigus disorders represent the paradigm of   immunobullous 
skin disease. The pemphigus diseases include pemphigus 
vulgaris (PV), pemphigus foliaceus (PF) and paraneoplastic 
pemphigus (PNP), all of which are associated with antibodies 
directed towards cell-cell adhesion molecules. The pathogen-
esis of both PV and PF has been well characterized and is 
dependent on the development of pathogenic anti-desmoglein 
antibodies, which disrupt keratinocyte-keratinocyte adhe-
sion leading to the clinical findings of blisters and erosions Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
138
Bennett et al
that of 17 patients treated, 9 were free of disease for at least 
six months.13 Only one patient did not respond, and one died 
of an infectious complication five months after treatment. 
Most patients received rituximab 375 mg/m2 weekly for 
4   consecutive weeks. Their review suggested that not only 
could rituximab successfully treat PV but also that a single 
cycle could induce long-term remission.
Subsequent reports have demonstrated the efficacy of 
rituximab in the treatment of PV. Ahmed and colleagues 
treated 11 patients with rituximab combined with intrave-
nous immune globulin producing long-term remissions in 
nine patients, all of whom had rapid and sustained loss of 
desmoglein antibodies coincident with the clinical resolu-
tion and tapering of corticosteroids.14 Joly and colleagues 
similarly showed the dramatic response to rituximab alone 
(375 mg/m2 × 4 weekly infusions) in steroid-refractory PV 
and PF.15 In their study, 18 of 21 patients obtained complete 
remission after three months and most demonstrated a 
stark reduction in desmoglein autoantibodies. In both studies, 
responses tended to correlate with the reduction in autoan-
tibodies. Mouquet and colleagues later reported a thorough 
study of the immunologic effects of rituximab treatment on 
the patients reported by Joly et al.15,16 They demonstrated, as 
expected, a rapid depletion of peripheral B-cells and a drop 
in IgM after therapy with rituximab. They also demonstrated 
that while anti-desmoglein antibodies dropped, antibodies 
directed towards pathogens did not, and B-cell reconstitu-
tion was not necessarily associated with the redevelopment 
of pathogenic autoantibodies. Also of interest, was their 
observation that some “complete responders” maintained 
detectable levels of desmoglein autoantibodies, suggesting 
that other, non-antibody-mediated mechanisms were at play 
in the pathogenesis of the disease. The obvious corollary is 
that rituximab must have immunomodulatory effects beyond 
the simple depletion of pathogenic antibodies. In fact, Eming 
and colleagues treated 11 PV patients and showed that ritux-
imab induced the expected clinical improvement associated 
with B-cell and autoantibody depletion and also indirectly 
decreased the frequency of autoreactive CD4+ T-cells.17 
The authors presume that B-cells act as antigen presenting 
cells in the pathogenesis of the disease.
PNP is, as the name implies, a paraneoplastic syndrome 
with a diverse clinical presentation. The disease virtually 
always presents with severe stomatitis, although other cuta-
neous findings vary from lichenoid papules and plaques to 
frank blistering and erosions. Palms, soles and paronychial 
tissues may also be affected. The disease has been associ-
ated with many malignancies, although non-Hodgkin’s 
Figure 2 Pemphigus vulgaris. A patient demonstrating mucosal erosions (A) and 
cutaneous blistering (B).(Image courtesy of Dr Ronald Grimwood).
(Figure 2). PF does not involve mucous membranes and 
is associated with autoantibodies targeting desmoglein-1. 
PV, in contrast, is associated with pathogenic antibodies 
targeting desmoglein-3, which is required for keratinocyte-
keratinocyte adhesion in mucosal epithelium. Patients with 
PV also demonstrate dsg-1 autoantibodies that, in combina-
tion with dsg-3 autoantibodies, produce epidermal bullae. 
As an antibody-mediated disorder, pemphigus has been 
an attractive target for B-cell directed therapies, including 
rituximab.12
Of all the skin diseases reported to have been   successfully 
treated with rituximab, PV has been the most frequently 
described and the best studied. PV is a life-threatening 
  illness that requires aggressive and long-term therapy with 
corticosteroids and immunosuppressive medications. While 
the disease itself is fatal if left untreated, the treatment of 
the disease is associated with significant morbidity. Some 
patients also demonstrate a treatment-resistant disease. 
El Tal and colleagues reviewed 11 reports of the use of 
rituximab to treat PV between 2002 and 2005 and found Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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lymphoma, chronic lymphocytic leukemia (CLL) and 
Castleman’s disease are most frequently reported.18 Other 
organ systems, usually the lungs, are frequently involved, 
leading to the suggestion that the name paraneoplastic 
autoimmune   multi-organ syndrome is more descriptive.19 
The   pathogenesis of the disease is quite complex. Autoan-
tibodies to many adhesion molecules have been described, 
and cytotoxic T-cells have also been found to play an 
important role.20 Case reports have demonstrated both suc-
cess and failure in the treatment of PNP with rituximab.21 
Two authors of this review (DB and CC) have encountered 
a patient with progressive PNP despite prior treatment of 
CLL with rituximab.22
Other immunobullous disorders
Bullous pemphigoid and epidermolysis 
bullosa acquisita
Bullous pemphigoid (BP) and epidermolysis bullosa acquisita 
(EBA) are blistering disorders associated with autoantibodies 
to bullous pemphigoid antigens (BPAG-1 and BPAG 2) and 
type VII collagen, respectively. The successful treatment of 
bullous pemphigoid with rituximab has been reported in both 
adults and in a child.23,24 At least two case reports describe 
the successful treatment of refractory EBA in adults with 
rituximab.25,26 All of the adults were treated with rituximab 
375 mg/m2 for four weeks.
Schmidt and colleagues reported additional cases of immu-
nobullous disease treated with rituximab: two BP, one adult and 
one child; four PV; and one mucous membrane pemphigoid 
(MMP).27 Of note, three of these patients developed severe side 
effects, including one patient with fatal pneumonia. Mucous 
membrane pemphigoid is an immunobullous disorder associ-
ated with autoantibodies targeting epidermal-dermal basement 
membrane antigens. The treatment of MMP with rituximab 
has been described in at least one additional patient.28
Atopic dermatitis
Atopic dermatitis (AD) is a chronic skin disorder manifested 
by severe itching, a chronic course, and an association with 
skin barrier defects. The disease is associated with food 
allergy, asthma, and allergic rhinitis, and most patients with 
the disease develop elevated IgE levels. The mainstay of 
treatment involves topical therapies, both anti-inflammatory 
and moisturizing, although many patients require systemic 
medications, including corticosteroids, cyclosporine and 
mycophenolate.29 Simon and colleagues reported the suc-
cessful treatment of severe AD with rituximab (1000 mg IV 
two weeks apart) in six patients.30 All patients demonstrated 
significant clinical and histological improvement despite only 
a 50% reduction in cutaneous B-cells. Allergen-specific IgE 
levels were also unchanged. This suggests that the behavior 
of B-cells as antigen presenting cells and activators of T-cells 
plays an important role in the pathogenesis of AD.
Sediva and colleagues subsequently described two severe 
AD cases that failed to respond significantly to rituximab 
treatment.31 This observation may be explained by the lower 
dose of rituximab (500 mg two weeks apart) used and by 
the fact that their patients had a particularly severe form of 
the disease. It also highlights the importance of overcoming 
reporting bias to share negative results.
Other inflammatory skin diseases
The successful use of rituximab in the treatment of   multiple 
other skin disorders has been reported. These include 
  dermatomyositis, systemic sclerosis (scleroderma), lupus, 
and multiple forms of vasculitis. These disorders are of poorly 
defined pathogenesis, affect multiple organs systems, and 
are frequently encountered or managed by dermatologists 
due to severe skin manifestations. The literature supporting 
the use of rituximab for these disorders varies from isolated 
case reports to small controlled trials.
A report of three cases of dermatomyositis treated 
with rituximab (375 mg/m2 × 4 doses) demonstrated sig-
nificant improvement in skin disease.32 However, a pilot 
trial involving eight patients using 1 g infused 14 days 
apart failed to show similar improvement.33 Others report 
success with rituximab in the treatment of both skin and 
muscle disease.34 The use of rituximab in the treatment 
of systemic sclerosis has recently been reviewed.35 The 
authors review four uncontrolled trials, one open-label 
randomized controlled trial, and one case report and 
found inconsistent improvement in skin thickening and 
interstitial lung disease. Further trials for both diseases 
are warranted.
The primary vasculitis disorders are a heterogeneous 
group of inflammatory autoimmune disorders unified by 
necrotizing destruction of blood vessels. While some are 
benign and self-limited, others are chronic, recalcitrant 
to treatment, and associated with significant morbidity 
and mortality. The nature of the clinical disease varies 
depending on the organ systems involved and the chronic-
ity of the disease. Multiple authors report the successful 
use of rituximab in various vasculitic disorders, including 
  Henoch-Shoenlein purpura, cryoglobulinemic vasculi-
tis, urticarial vasculitis, and antineutrophil cytoplasmic 
antibody-associated vasculitis.36–39 Interestingly, vascu-Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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litis has also been reported as a side effect of rituximab 
therapy.41
Cutaneous lupus erythematosus may occur in patients 
with or without a diagnosis of systemic lupus erythemato-
sus (SLE). Risselada and Kallenberg report two patients 
with SLE whose severe skin manifestations responded to 
rituximab.41 Uthman and colleagues reported the improve-
ment of severe subacute cutaneous lupus erythematosus 
associated with SLE after treatment with rituximab.42 
Rituximab may be considered in patients with severe lupus 
skin disease that is recalcitrant to topical medications, 
antimalarials, and more conventional immunosuppressive 
medications.
New directions
The use of rituximab in severe autoimmune skin disorders 
has provided a welcome clinical option. Dosing has mir-
rored either the experience with lymphoid malignancy 
(375 mg/m2 × 4 weeks) or autoimmune disease (1000 mg × 2 
given two weeks apart). Both dosing schema lead to an 
increased t½ of rituximab on subsequent infusion. In our 
introductory case we emphasized that the pathophysiology 
of LV is controversial. Some emphasize an inflammatory 
mechanism while others emphasize hypercoagulability. In 
reality, inflammation and procoagulant states are not easily 
separated. When a disease such as RA or pemphigus vulgaris, 
previously treated with therapies directed toward cellular 
immunity, responds to rituximab then our fundamental 
understanding of pathophysiology is altered as well. T-cells 
and B-cells interact, and cognitive separation of the two 
systems is conceptually necessary although likely artificial. 
Our hope is that this brief review will help to place the use 
of rituximab in severe skin disorders into historical and sci-
entific context and that we will encourage others to report 
findings, both positive and negative in the treatment of rare 
diseases such as LV .
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